aPALACE 1-3 pooled analysis. LOCF; includes patients randomized to OTEZLA 30 mg BID or placebo at baseline.
bData as observed; includes patients who were randomized to OTEZLA 30 mg BID at baseline and remained on treatment for 156 weeks.
cP = 0.0002 vs placebo.
dMCID for BASDAI = -1.1 point improvement.2
During the placebo-controlled period, at week 16, patients taking OTEZLA 30 mg BID achieved a greater mean decrease in BASDAI score vs patients taking placebo (-1.53 vs -0.91; P = 0.0173).1†
*Pooled patient data from PALACE 1-3; BASDAI score was an exploratory measure in the subset of patients with axial symptoms and a baseline BASDAI score of >4 (n=454); BASDAI mean scores at BL were 6.6 for OTEZLA 30 mg BID and 6.4 for placebo.
BASDAI, Bath Ankylosing Disease Activity Index; BID, twice daily; BL, baseline; LOCF, last observation carried forward; MCID, minimum clinically important difference; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).